INMED PHARMACEUTICALS INC (INM) Stock Price, Quote, News and Overview
NASDAQ:INM - Nasdaq - CA4576377002 - Common Stock - Currency: USD
INM Quote, Performance and Key Statistics
NASDAQ:INM (5/7/2025, 4:30:02 PM)
2.736
-0.17 (-5.93%)
The current stock price of INM is 2.736 USD. In the past month the price increased by 22.22%. In the past year, price decreased by -48.02%.
INM Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 56.45 | 736.32B | ||
| JNJ | JOHNSON & JOHNSON | 15.65 | 378.47B | ||
| NVO | NOVO-NORDISK A/S-SPONS ADR | 19.58 | 299.86B | ||
| NVS | NOVARTIS AG-SPONSORED ADR | 13.44 | 220.62B | ||
| AZN | ASTRAZENECA PLC-SPONS ADR | 18.84 | 217.24B | ||
| MRK | MERCK & CO. INC. | 10.16 | 199.10B | ||
| PFE | PFIZER INC | 7.1 | 129.25B | ||
| SNY | SANOFI-ADR | 13.61 | 127.96B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 6.49 | 96.91B | ||
| GSK | GSK PLC-SPON ADR | 6.77 | 75.21B | ||
| ZTS | ZOETIS INC | 25.91 | 69.58B | ||
| HLN | HALEON PLC-ADR | 21.96 | 48.52B |
Related stock screener links
About INM
Company Profile
InMed Pharmaceuticals, Inc. engages in the provision of biopharmaceutical research. The company is headquartered in Vancouver, British Columbia. The company went IPO on 2001-06-21. The company develops a pipeline of small molecule drug candidates targeting the CB1/CB2 receptors. Its InMed Pharmaceuticals segment is engaged in the research and development of small molecule pharmaceuticals drug candidates. Its BayMedica Commercial segment is engaged in the manufacturing technologies to produce and commercialize bulk rare cannabinoids for sale as ingredients in the health and wellness industry. Its pharmaceutical pipeline consists of three programs, with drug candidates targeting Alzheimer’s disease, dry age-related macular degeneration, and Epidermolysis Bullosa. Its INM-901 is a drug candidate being developed as a potential treatment for Alzheimer’s disease. Its INM-089 is cannabinoid analog being studied for its potential as a treatment for age-related macular degeneration. Its INM-755 is a cannabinol topical cream which has completed Phase 2 clinical trial studies for the treatment of epidermolysis bullosa.
Company Info
INMED PHARMACEUTICALS INC
1445-885 West Georgia St.
Vancouver BRITISH COLUMBIA V6C1B4 CA
CEO: Eric Adams
Employees: 13
Phone: 16046697207
INMED PHARMACEUTICALS INC / INM FAQ
What is the stock price of INMED PHARMACEUTICALS INC today?
The current stock price of INM is 2.736 USD. The price decreased by -5.93% in the last trading session.
What is the ticker symbol for INMED PHARMACEUTICALS INC stock?
The exchange symbol of INMED PHARMACEUTICALS INC is INM and it is listed on the Nasdaq exchange.
On which exchange is INM stock listed?
INM stock is listed on the Nasdaq exchange.
What is INMED PHARMACEUTICALS INC worth?
INMED PHARMACEUTICALS INC (INM) has a market capitalization of 3.31M USD. This makes INM a Nano Cap stock.
How many employees does INMED PHARMACEUTICALS INC have?
INMED PHARMACEUTICALS INC (INM) currently has 13 employees.
What are the support and resistance levels for INMED PHARMACEUTICALS INC (INM) stock?
INMED PHARMACEUTICALS INC (INM) has a resistance level at 2.95. Check the full technical report for a detailed analysis of INM support and resistance levels.
Should I buy INMED PHARMACEUTICALS INC (INM) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of INM, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of INM, evaluating the profitability, health, valuation and growth aspects
- INMED PHARMACEUTICALS INC (INM) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- INMED PHARMACEUTICALS INC (INM) Sales and EPS estimates to see what analysts future expectations are.
- INMED PHARMACEUTICALS INC (INM) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- INMED PHARMACEUTICALS INC (INM) Insider and Institutional Ownership to learn about the owners and their transactions.
- INMED PHARMACEUTICALS INC (INM) Stock Chart to make your own analysis
- INMED PHARMACEUTICALS INC (INM) Latest news and press-releases to stay up to date.
Does INMED PHARMACEUTICALS INC (INM) stock pay dividends?
INM does not pay a dividend.
When does INMED PHARMACEUTICALS INC (INM) report earnings?
INMED PHARMACEUTICALS INC (INM) will report earnings on 2025-05-12.
What is the Price/Earnings (PE) ratio of INMED PHARMACEUTICALS INC (INM)?
INMED PHARMACEUTICALS INC (INM) does not have a PE ratio as the earnings reported over the last twelve months were negative (-13.97).
What is the Short Interest ratio of INMED PHARMACEUTICALS INC (INM) stock?
The outstanding short interest for INMED PHARMACEUTICALS INC (INM) is 3.63% of its float. Check the ownership tab for more information on the INM short interest.
INM Technical Analysis
ChartMill assigns a technical rating of 2 / 10 to INM. When comparing the yearly performance of all stocks, INM is a bad performer in the overall market: 84.58% of all stocks are doing better.
INM Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to INM. INM scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.
INM Financial Highlights
Over the last trailing twelve months INM reported a non-GAAP Earnings per Share(EPS) of -13.97. The EPS decreased by -170.37% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -93.07% | ||
| ROE | -128.01% | ||
| Debt/Equity | 0 |
INM Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 45% to INM. The Buy consensus is the average rating of analysts ratings from 8 analysts.